{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:32:03Z","timestamp":1782192723125,"version":"3.54.5"},"reference-count":241,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003030","name":"AGAUR","doi-asserted-by":"publisher","award":["2017SGR135"],"award-info":[{"award-number":["2017SGR135"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00034"],"award-info":[{"award-number":["PI19\/00034"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI18\/00021"],"award-info":[{"award-number":["FI18\/00021"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2019-104695RB-I00"],"award-info":[{"award-number":["PID2019-104695RB-I00"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["AECC GC16173697BIGA"],"award-info":[{"award-number":["AECC GC16173697BIGA"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n AECC","doi-asserted-by":"publisher","award":["GC16173697BIGA"],"award-info":[{"award-number":["GC16173697BIGA"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.exphem.2021.12.191","type":"journal-article","created":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T17:56:05Z","timestamp":1638726965000},"page":"3-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Recent advances in T-cell lymphoid neoplasms"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4801-6899","authenticated-orcid":false,"given":"Anna","family":"Bigas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Rodriguez-Sevilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2897-4099","authenticated-orcid":false,"given":"Lluis","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2021.12.191_bib0001","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1182\/blood-2016-05-716480","article-title":"A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation","volume":"128","author":"Nestorowa","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0002","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.smim.2008.05.002","article-title":"T and B lymphocyte differentiation from hematopoietic stem cell","volume":"20","author":"Lai","year":"2008","journal-title":"Semin Immunol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0003","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.stem.2015.05.003","article-title":"Functionally distinct subsets of lineage-biased multipotent progenitors control blood production in normal and regenerative conditions","volume":"17","author":"Pietras","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2021.12.191_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60606-9","article-title":"Molecular and cellular events in early thymocyte development","volume":"69","author":"Rodewald","year":"1998","journal-title":"Adv Immunol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0005","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0952-7915(99)00064-3","article-title":"Lymphoid precursors","volume":"12","author":"Akashi","year":"2000","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0006","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1073\/pnas.0602024103","article-title":"A multistep adhesion cascade for lymphoid progenitor cell homing to the thymus","volume":"103","author":"Scimone","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2021.12.191_bib0007","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/imr.12417","article-title":"Hematopoiesis and T-cell specification as a model developmental system","volume":"271","author":"Rothenberg","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.exphem.2021.12.191_bib0008","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0952-7915(99)00067-9","article-title":"Notch signaling in T cell development","volume":"12","author":"Deftos","year":"2000","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0009","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.smim.2012.02.002","article-title":"Intrathymic IL-7: the where, when, and why of IL-7 signaling during T cell development","volume":"24","author":"Hong","year":"2012","journal-title":"Semin Immunol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0010","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/ni1313","article-title":"Aifantis I. Hedgehog signaling controls thymocyte progenitor homeostasis and differentiation in the thymus","volume":"7","author":"El Andaloussi","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0011","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","article-title":"Human T cell development, localization, and function throughout life","volume":"48","author":"Kumar","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2021.12.191_bib0012","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","article-title":"Obstacles posed by the tumor microenvironment to T cell activity: A case for synergistic therapies","volume":"31","author":"Anderson","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2021.12.191_bib0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.exphem.2021.12.191_bib0014","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1615\/CritRevOncog.2013010597","article-title":"Immunosenescence and cancer","volume":"18","author":"Fulop","year":"2013","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.exphem.2021.12.191_bib0015","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.immuni.2017.03.010","article-title":"Successful and maladaptive T cell aging","volume":"46","author":"Goronzy","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2021.12.191_bib0016","doi-asserted-by":"crossref","first-page":"7424","DOI":"10.3390\/ijms21197424","article-title":"T cell activation machinery: Form and function in natural and engineered immune receptors","volume":"21","author":"Chandler","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2021.12.191_bib0017","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3389\/fimmu.2019.01719","article-title":"T cell dysfunction in cancer immunity and immunotherapy","volume":"10","author":"Xia","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.exphem.2021.12.191_bib0018","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10875-012-9844-3","article-title":"Critical differences in hematopoiesis and lymphoid development between humans and mice","volume":"33","author":"Parekh","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0019","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.immuni.2020.03.019","article-title":"Integrated scRNA-Seq identifies human postnatal thymus seeding progenitors and regulatory dynamics of differentiating immature thymocytes","volume":"52","author":"Lavaert","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2021.12.191_bib0020","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.immuni.2020.05.010","article-title":"Single-cell RNA-Seq mapping of human thymopoiesis reveals lineage specification trajectories and a commitment spectrum in T cell development","volume":"52","author":"Le","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2021.12.191_bib0021","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2021.12.191_bib0022","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1182\/blood-2011-03-343947","article-title":"Cell of origin strongly influences genetic selection in a mouse model of T-ALL","volume":"118","author":"Berquam-Vrieze","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0023","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1182\/blood-2010-06-292300","article-title":"Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance","volume":"116","author":"Chiu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0024","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ccell.2016.11.002","article-title":"Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia","volume":"30","author":"Ebinger","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2021.12.191_bib0025","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2021.12.191_bib0026","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13059-020-02192-z","article-title":"The evolution of relapse of adult T cell acute lymphoblastic leukemia","volume":"21","author":"Sent\u00eds","year":"2020","journal-title":"Genome Biol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0027","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.exphem.2021.12.191_bib0028","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.cell.2013.05.041","article-title":"The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability","volume":"153","author":"King","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2021.12.191_bib0029","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ccell.2017.10.004","article-title":"A paradoxical tumor-suppressor role for the Rac1 exchange factor Vav1 in T cell acute lymphoblastic leukemia","volume":"32","author":"Robles-Valero","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2021.12.191_bib0030","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrclinonc.2015.175","article-title":"The influence of subclonal resistance mutations on targeted cancer therapy","volume":"13","author":"Schmitt","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0031","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/bloodadvances.2017005538","article-title":"Homeobox protein TLX3 activates miR-125b expression to promote T-cell acute lymphoblastic leukemia","volume":"1","author":"Renou","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2021.12.191_bib0032","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","article-title":"The genetics and molecular biology of T-ALL","volume":"129","author":"Girardi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0033","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/ng.542","article-title":"PHF6 mutations in T-cell acute lymphoblastic leukemia","volume":"42","author":"Van Vlierberghe","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2021.12.191_bib0034","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/leu.2010.247","article-title":"PHF6 mutations in adult acute myeloid leukemia","volume":"25","author":"Van Vlierberghe","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2021.12.191_bib0035","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.18632\/oncotarget.2218","article-title":"Mutational spectrum of adult T-ALL","volume":"6","author":"Neumann","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2021.12.191_bib0036","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/gcc.22039","article-title":"The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL","volume":"52","author":"Grossmann","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.exphem.2021.12.191_bib0037","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ccr.2010.08.006","article-title":"The Notch\/Hes1 pathway sustains NF-\u03baB activation through CYLD repression in T cell leukemia","volume":"18","author":"Espinosa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2021.12.191_bib0038","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/1097-0142(197608)38:2<672::AID-CNCR2820380208>3.0.CO;2-C","article-title":"Remission induction in adult acute lymphocytic leukemia: Use of vincristine and prednisone alone","volume":"38","author":"Scavino","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2021.12.191_bib0039","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1200\/jco.2006.24.18_suppl.6585","article-title":"A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia\/lymphoma (T-ALL) and other leukemias","volume":"24","author":"Deangelo","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0040","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1182\/blood.V124.21.968.968","article-title":"The safety and activity of BMS-906024, a gamma secretase inhibitor (GSI) with anti-notch activity, in patients with relapsed T-cell acute lymphoblastic leukemia (T-ALL): Initial results of a phase 1 trial","volume":"124","author":"Zweidler-McKay","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0041","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm.1900","article-title":"Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia","volume":"15","author":"Real","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2021.12.191_bib0042","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1158\/1535-7163.MCT-11-0938","article-title":"Preclinical analysis of the \u03b3-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia","volume":"11","author":"Samon","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.exphem.2021.12.191_bib0043","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5601396","article-title":"Notch\/CXCR4 partnership in acute lymphoblastic leukemia progression","volume":"2019","author":"Tsaouli","year":"2019","journal-title":"J Immunol Res"},{"key":"10.1016\/j.exphem.2021.12.191_bib0044","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41375-019-0548-z","article-title":"Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell\/CD19\/CD22-negative acute lymphoblastic leukemia","volume":"34","author":"Ofran","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2021.12.191_bib0045","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0046","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","article-title":"Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia","volume":"133","author":"S\u00e1nchez-Mart\u00ednez","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0047","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell\u2013directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0048","doi-asserted-by":"crossref","first-page":"CT052","DOI":"10.1158\/1538-7445.AM2020-CT052","article-title":"Abstract CT052: Clinical safety and efficacy study of TruUCAR\u2122 GC027: the first-in-human, universal CAR-T therapy for adult relapsed\/refractory T-cell acute lymphoblastic leukemia (r\/r T-ALL)","volume":"80","author":"Wang","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2021.12.191_bib0049","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jgg.2019.06.007","article-title":"Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells","volume":"46","author":"Gao","year":"2019","journal-title":"J Genet Genom"},{"key":"10.1016\/j.exphem.2021.12.191_bib0050","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0051","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccr.2012.09.016","article-title":"Therapeutic targeting of the cyclin D3:CDK4\/6 complex in T cell leukemia","volume":"22","author":"Sawai","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2021.12.191_bib0052","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-15-2869","article-title":"Synergistic drug combinations with a CDK4\/6 inhibitor in T-cell acute lymphoblastic leukemia","volume":"23","author":"Pikman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2021.12.191_bib0053","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1080\/10428194.2019.1617860","article-title":"Insights into the cellular pharmacological properties of the BET-inhibitor OTX015\/MK-8628 (birabresib), alone and in combination, in leukemia models","volume":"60","author":"Astorgues-Xerri","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2021.12.191_bib0054","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1158\/1078-0432.CCR-20-1315","article-title":"The XPO1 inhibitor KPT-8602 synergizes with dexamethasone in acute lymphoblastic leukemia","volume":"26","author":"Verbeke","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2021.12.191_bib0055","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1158\/1078-0432.CCR-14-0259","article-title":"Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts","volume":"20","author":"Suryani","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2021.12.191_bib0056","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2021.12.191_bib0057","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0058","first-page":"1015","article-title":"Treatment of lymphoblastic lymphoma in adults","volume":"23","author":"Sweetenham","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.exphem.2021.12.191_bib0059","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0060","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ejh.12722","article-title":"Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment","volume":"96","author":"Bassan","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0061","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0062","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/blood.V57.6.1105.1105","article-title":"Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"57","author":"Bernard","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0063","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1365-2141.2011.08788.x","article-title":"Chromosome abnormalities in advanced stage T-cell lymphoblastic lymphoma of children and adolescents: a report from Japanese Paediatric Leukaemia\/Lymphoma Study Group (JPLSG) and review of the literature","volume":"154","author":"Sekimizu","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0064","first-page":"416","article-title":"Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report","volume":"95","author":"Reiter","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0065","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0066","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.27972","article-title":"Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia","volume":"119","author":"Hopfinger","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2021.12.191_bib0067","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2007-07-101519","article-title":"High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia","volume":"111","author":"Herling","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0068","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11899-020-00566-5","article-title":"Advances and perspectives in the treatment of T-PLL","volume":"15","author":"Braun","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.exphem.2021.12.191_bib0069","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(73)93135-8","article-title":"Prolymphocytic leukaemia of B and T cell type","volume":"2","author":"Catovsky","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2021.12.191_bib0070","doi-asserted-by":"crossref","first-page":"104664","DOI":"10.18632\/oncotarget.22272","article-title":"Advances in the understanding and management of T-cell prolymphocytic leukemia","volume":"8","author":"Laribi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2021.12.191_bib0071","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/gcc.22313","article-title":"Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker","volume":"55","author":"Stengel","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.exphem.2021.12.191_bib0072","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0073","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood.2019000402","article-title":"Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia","volume":"134","author":"Staber","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0074","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","article-title":"The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype","volume":"12","author":"Mercieca","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0075","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood.V78.12.3269.3269","article-title":"Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia","volume":"78","author":"Matutes","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0076","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1182\/blood-2011-08-372854","article-title":"Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route","volume":"118","author":"Dearden","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0077","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","article-title":"How I treat prolymphocytic leukemia","volume":"120","author":"Dearden","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0078","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/ejh.12462","article-title":"Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation?","volume":"94","author":"Herling","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0079","doi-asserted-by":"crossref","first-page":"293ra102","DOI":"10.1126\/scitranslmed.aaa5079","article-title":"Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia","volume":"7","author":"Hasanali","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2021.12.191_bib0080","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41467-017-02688-6","article-title":"Actionable perturbations of damage responses by TCL1\/ATM and epigenetic lesions form the basis of T-PLL","volume":"9","author":"Schrader","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2021.12.191_bib0081","doi-asserted-by":"crossref","first-page":"626","DOI":"10.18632\/oncotarget.26595","article-title":"The dawn of a new era in treating T-PLL","volume":"10","author":"Schrader","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2021.12.191_bib0082","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/leu.2017.252","article-title":"Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling","volume":"32","author":"Andersson","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2021.12.191_bib0083","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1080\/10428194.2019.1594220","article-title":"Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1\/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation","volume":"60","author":"Gomez-Arteaga","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2021.12.191_bib0084","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood.V126.23.5486.5486","article-title":"Refractory T-cell prolymphocytic leukemia with JAK3 mutation: in vitro and clinical synergy of tofacitinib and ruxolitinib","volume":"126","author":"Wei","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0085","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood-2017-05-785683","article-title":"First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia","volume":"130","author":"Boidol","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0086","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/hon.161_2631","article-title":"The combination of venetoclax and ibrutinib is effective in relapsed\/refractory T-prolymphocytic leukemia and influences BCL-2-family member dependencies","volume":"37","author":"Kornauth","year":"2019","journal-title":"Hematol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2021.12.191_bib0087","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood-2019-126773","article-title":"Characterizing the Anti-apoptotic dependencies of T-cell prolymphocytic leukemia identifies HDAC and JAK\/STAT pathway inhibitors as promising combination partners to augment Bcl-2 targeted killing by venetoclax","volume":"134","author":"Herbaux","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0088","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/10428194.2019.1660967","article-title":"First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL)","volume":"61","author":"Alfayez","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2021.12.191_bib0089","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14712598.2019.1572746","article-title":"Development of new agents for peripheral T-cell lymphoma","volume":"19","author":"Ito","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.exphem.2021.12.191_bib0090","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/s41467-018-04356-9","article-title":"Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models","volume":"9","author":"Ng","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2021.12.191_bib0091","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","article-title":"Phase I study of the novel enhancer of Zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors","volume":"25","author":"Yap","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2021.12.191_bib0092","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.1038\/bcj.2016.59","article-title":"Go RS. A population-based study of large granular lymphocyte leukemia","volume":"6","author":"Shah","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2021.12.191_bib0093","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1172\/JCI9940","article-title":"Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression","volume":"107","author":"Epling-Burnette","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2021.12.191_bib0094","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2012-12-474577","article-title":"Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia","volume":"121","author":"Rajala","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0095","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1038\/sj.onc.1208122","article-title":"ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL)","volume":"23","author":"Epling-Burnette","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2021.12.191_bib0096","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2005-08-3076","article-title":"Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis","volume":"107","author":"Schade","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0097","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1365-2141.2000.01934.x","article-title":"Clinicopathological features of aggressive large granular lymphocyte leukaemia resemble Fas ligand transgenic mice","volume":"108","author":"Lamy","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0098","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2010-07-296962","article-title":"How I treat LGL leukemia","volume":"117","author":"Lamy","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0099","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1182\/blood-2016-08-692590","article-title":"LGL leukemia: from pathogenesis to treatment","volume":"129","author":"Lamy","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0100","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2021.12.191_bib0101","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood-2012-06-435297","article-title":"STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia","volume":"120","author":"Jerez","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0102","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/leu.2014.298","article-title":"Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998)","volume":"29","author":"Loughran","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2021.12.191_bib0103","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/sj.leu.2403262","article-title":"Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells","volume":"18","author":"Suzuki","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2021.12.191_bib0104","first-page":"1343","article-title":"Aggressive natural killer cell leukemia: clinical features and treatment outcome","volume":"87","author":"Song","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2021.12.191_bib0105","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1080\/10428190400004513","article-title":"Aggressive natural killer-cell leukemia: report of five cases and review of the literature","volume":"45","author":"Ruskova","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2021.12.191_bib0106","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/modpathol.2017.37","article-title":"EBV-negative aggressive NK-cell leukemia\/lymphoma: a clinical and pathological study from a single institution","volume":"30","author":"Gao","year":"2017","journal-title":"Modern Pathol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0107","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/PAS.0000000000000735","article-title":"EBV-Negative aggressive NK-cell leukemia\/lymphoma: Clinical, pathologic, and genetic features","volume":"41","author":"Nicolae","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0108","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2009-05-221275","article-title":"Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK\/T-cell lymphoma, nasal type","volume":"115","author":"Huang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0109","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1038\/ncomms7025","article-title":"Activating mutations of STAT5B and STAT3 in lymphomas derived from \u03b3\u03b4-T or NK cells","volume":"6","author":"K\u00fc\u00e7\u00fck","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2021.12.191_bib0110","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/leu.2013.157","article-title":"JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma","volume":"28","author":"Bouchekioua","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2021.12.191_bib0111","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41467-018-03987-2","article-title":"Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target","volume":"9","author":"Dufva","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2021.12.191_bib0112","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/cr.2017.146","article-title":"Integrated genomic analysis identifies deregulated JAK\/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia","volume":"28","author":"Huang","year":"2018","journal-title":"Cell Res"},{"key":"10.1016\/j.exphem.2021.12.191_bib0113","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/10428194.2014.905772","article-title":"Aggressive mature natural killer cell neoplasms: report on a series of 12 European patients with emphasis on flow cytometry based immunophenotype and DNA content of neoplastic natural killer cells","volume":"56","author":"Lima","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2021.12.191_bib0114","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/PAT.0000000000000275","article-title":"Extranodal NK\/T cell lymphoma and aggressive NK cell leukaemia: evidence for their origin on CD56+bright CD16\u2013\/+dim NK cells","volume":"47","author":"Lima","year":"2015","journal-title":"Pathology"},{"key":"10.1016\/j.exphem.2021.12.191_bib0115","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2021.12.191_bib0116","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/PAS.0000000000001518","article-title":"Genomic and immunophenotypic landscape of aggressive NK-cell leukemia","volume":"44","author":"El Hussein","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0117","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/gcc.20245","article-title":"Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma\/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk\/T-cell lymphoma, nasal type","volume":"44","author":"Nakashima","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.exphem.2021.12.191_bib0118","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.3390\/cancers12102900","article-title":"Aggressive NK cell leukemia: Current state of the art","volume":"12","author":"El Hussein","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.exphem.2021.12.191_bib0119","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-016-0271-4","article-title":"L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia","volume":"9","author":"Jung","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0120","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1349-7006.2012.02251.x","article-title":"Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation","volume":"103","author":"Ishida","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.exphem.2021.12.191_bib0121","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/PAS.0000000000000634","article-title":"Clinicopathologic characterization of aggressive natural killer cell leukemia involving different tissue sites","volume":"40","author":"Gao","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0122","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.bbmt.2017.01.082","article-title":"Allogeneic hematopoietic cell transplantation for aggressive NK-cell leukemia. A CIBMTR analysis","volume":"23","author":"Hamadani","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2021.12.191_bib0123","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41408-017-0021-z","article-title":"Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes","volume":"7","author":"Tang","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2021.12.191_bib0124","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2141.1990.tb02615.x","article-title":"Aggressive natural killer cell leukaemia\/lymphoma: report of four cases and review of the literature. Possible existence of a new clinical entity originating from the third lineage of lymphoid cells","volume":"75","author":"Imamura","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0125","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0126","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2021.12.191_bib0127","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front Microbiol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0128","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5858\/arpa.2012-0379-RS","article-title":"Adult T-cell leukemia\/lymphoma","volume":"138","author":"Qayyum","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.exphem.2021.12.191_bib0129","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fmicb.2020.01124","article-title":"Epidemiology of HTLV-1 infection and ATL in Japan: An update","volume":"11","author":"Iwanaga","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0130","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/cncr.32556","article-title":"Epidemiology and survival trend of adult T-cell leukemia\/lymphoma in the United States","volume":"126","author":"Shah","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2021.12.191_bib0131","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1111\/cas.13303","article-title":"Genetic alterations in adult T-cell leukemia\/lymphoma","volume":"108","author":"Kogure","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.exphem.2021.12.191_bib0132","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/ng.3428","article-title":"The genomic landscape of adult T cell leukemia\/lymphoma","volume":"47","author":"Vicente","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2021.12.191_bib0133","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0134","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1084\/jem.20140987","article-title":"Gain-of-function CCR4 mutations in adult T cell leukemia\/lymphoma","volume":"211","author":"Nakagawa","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2021.12.191_bib0135","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2021.12.191_bib0136","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1002\/cncr.25147","article-title":"A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia\/lymphoma","volume":"116","author":"Phillips","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2021.12.191_bib0137","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdn696","article-title":"The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia\/lymphoma: analysis of 126 patients from the International Peripheral T-cell Lymphoma Project","volume":"20","author":"Suzumiya","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0138","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/cas.12735","article-title":"A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia\/lymphoma","volume":"106","author":"Ishitsuka","year":"2015","journal-title":"Cancer Sci"},{"key":"10.1016\/j.exphem.2021.12.191_bib0139","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1038\/bcj.2016.21","article-title":"Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma","volume":"6","author":"Ratner","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2021.12.191_bib0140","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0141","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1182\/blood-2011-03-345702","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"118","author":"Bazarbachi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0142","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia\u2013lymphoma: A multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0143","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1002\/acg2.5","article-title":"Pre- and posttransplant use of mogamulizumab in patients with aggressive adult T-cell leukemia-lymphoma: A statement from key opinion leaders in Japan","volume":"1","author":"Fuji","year":"2018","journal-title":"Adv Cell Gene Ther"},{"key":"10.1016\/j.exphem.2021.12.191_bib0144","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O'Connor","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0145","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.humpath.2018.01.005","article-title":"Hepatosplenic T-cell lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors","volume":"74","author":"Yabe","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0146","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1002\/ajh.24711","article-title":"Incidence, clinical findings, and survival of hepatosplenic T-cell lymphoma in the United States","volume":"92","author":"Durani","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0147","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood.V75.11.2213.2213","article-title":"Hepatosplenic T-cell lymphoma: sinusal\/sinusoidal localization of malignant cells expressing the T-cell receptor \u03b3\u03b4","volume":"75","author":"Farcet","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0148","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2019004118","article-title":"Hepatosplenic T-cell lymphoma: a rare but challenging entity","volume":"136","author":"Pro","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0149","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2003-05-1675","article-title":"Hepatosplenic \u03b3\u03b4 T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients","volume":"102","author":"Belhadj","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0150","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1038\/leu.2014.200","article-title":"Frequent STAT5B mutations in \u03b3\u03b4 hepatosplenic T-cell lymphomas","volume":"28","author":"Nicolae","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2021.12.191_bib0151","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1182\/blood-2011-12-396150","article-title":"Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets","volume":"119","author":"Travert","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0152","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/2159-8290.CD-16-0330","article-title":"The genetic basis of hepatosplenic T-cell lymphoma","volume":"7","author":"McKinney","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2021.12.191_bib0153","first-page":"ECR14","article-title":"Pentostatin (2\u2032-deoxycoformycin) for the treatment of hepatosplenic gammadelta T-cell lymphomas","volume":"90","author":"Corazzelli","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2021.12.191_bib0154","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdn751","article-title":"Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment","volume":"20","author":"Falchook","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2012.09.002","article-title":"Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience","volume":"13","author":"Voss","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.exphem.2021.12.191_bib0156","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2169\/internalmedicine.1266-18","article-title":"Successful bridging chemotherapy with gemcitabine, carboplatin, and dexamethasone before unrelated stem cell transplantation for hepatosplenic T-cell lymphoma","volume":"58","author":"Okuni","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.exphem.2021.12.191_bib0157","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1600-0609.2006.00646.x","article-title":"A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab","volume":"76","author":"Mittal","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0158","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2009.07606.x","article-title":"Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy","volume":"145","author":"Jiang","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0159","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/blood.2020005372","article-title":"Chromosome 20 loss is characteristic of breast implant-associated anaplastic large cell lymphoma","volume":"136","author":"Los-de Vries","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0160","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.exphem.2021.12.191_bib0161","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1097\/PAS.0b013e318222dfcd","article-title":"Type II enteropathy-associated T-cell lymphoma: A distinct aggressive lymphoma with frequent \u03b3\u03b4 T-cell receptor expression","volume":"35","author":"Chan","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0162","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/ajh.23213","article-title":"Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group","volume":"87","author":"Tse","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0163","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/leu.2016.13","article-title":"JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma","volume":"30","author":"Nairism\u00e4gi","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2021.12.191_bib0164","doi-asserted-by":"crossref","first-page":"12602","DOI":"10.1038\/ncomms12602","article-title":"Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations","volume":"7","author":"Roberti","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2021.12.191_bib0165","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1002\/cncr.26700","article-title":"Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973\u20132008","volume":"118","author":"Sharaiha","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2021.12.191_bib0166","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.critrevonc.2010.06.006","article-title":"Enteropathy-associated T-cell lymphoma","volume":"79","author":"Ferreri","year":"2011","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0167","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2011-02-335216","article-title":"Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project","volume":"118","author":"Delabie","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0168","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.dld.2012.12.001","article-title":"Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study","volume":"45","author":"Malamut","year":"2013","journal-title":"Digest Liver Dis"},{"key":"10.1016\/j.exphem.2021.12.191_bib0169","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2009-07-231324","article-title":"Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation","volume":"115","author":"Sieniawski","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0170","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1200\/JCO.2000.18.4.795","article-title":"Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center","volume":"18","author":"Gale","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0171","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cgh.2005.12.011","article-title":"Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma","volume":"4","author":"Al-Toma","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0172","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/01.LAB.0000090157.13040.58","article-title":"High frequency of genetic aberrations in enteropathy-type T-cell lymphoma","volume":"83","author":"Baumg\u00e4rtner","year":"2003","journal-title":"Lab Invest"},{"key":"10.1016\/j.exphem.2021.12.191_bib0173","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1053\/j.gastro.2007.03.036","article-title":"Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes","volume":"132","author":"Deleeuw","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.exphem.2021.12.191_bib0174","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1084\/jem.20160894","article-title":"Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2","volume":"214","author":"Moffitt","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2021.12.191_bib0175","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.5858\/arpa.2013-0242-CR","article-title":"Classic versus type II enteropathy-associated T-cell lymphoma: diagnostic considerations","volume":"137","author":"Arps","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.exphem.2021.12.191_bib0176","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s11899-016-0357-7","article-title":"Enteropathy-associated T-cell lymphoma","volume":"11","author":"Ondrejka","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.exphem.2021.12.191_bib0177","doi-asserted-by":"crossref","first-page":"e20050","DOI":"10.1097\/MD.0000000000020050","article-title":"Type II enteropathy-associated T cell lymphoma in the duodenum: A rare case report","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.exphem.2021.12.191_bib0178","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1093\/annonc\/mdh427","article-title":"Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma","volume":"15","author":"W\u00f6hrer","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0179","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1182\/bloodadvances.2020003218","article-title":"Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy","volume":"4","author":"Voorhees","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2021.12.191_bib0180","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0181","doi-asserted-by":"crossref","first-page":"137","DOI":"10.6004\/jnccn.2013.0021","article-title":"Brentuximab in the treatment of CD30-positive enteropathy-associated T-cell lymphoma","volume":"11","author":"Khalaf","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.exphem.2021.12.191_bib0182","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.5858\/arpa.2018-0275-RA","article-title":"Update on gastrointestinal lymphomas","volume":"142","author":"Weindorf","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.exphem.2021.12.191_bib0183","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1182\/blood-2013-07-512830","article-title":"Indolent T-cell lymphoproliferative disease of the gastrointestinal tract","volume":"122","author":"Perry","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0184","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/his.12596","article-title":"Recent advances in intestinal lymphomas","volume":"66","author":"Foukas","year":"2015","journal-title":"Histopathology"},{"key":"10.1016\/j.exphem.2021.12.191_bib0185","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/modpathol.2015.85","article-title":"Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan","volume":"28","author":"Tomita","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0186","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature08672","article-title":"Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes","volume":"463","author":"Dalgliesh","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2021.12.191_bib0187","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/ng.2894","article-title":"Identification of functional cooperative mutations of SETD2 in human acute leukemia","volume":"46","author":"Zhu","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2021.12.191_bib0188","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0189","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00277-019-03791-y","article-title":"Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma","volume":"98","author":"Yi","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0190","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/sj.leu.2402174","article-title":"CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis","volume":"15","author":"Raspadori","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2021.12.191_bib0191","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.pathol.2019.10.001","article-title":"T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract: review and update","volume":"52","author":"van Vliet","year":"2020","journal-title":"Pathology"},{"key":"10.1016\/j.exphem.2021.12.191_bib0192","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1182\/blood-2018-01-830968","article-title":"Recurrent STAT3\u2013JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract","volume":"131","author":"Sharma","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0193","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/1066896918785985","article-title":"Disease progression in a patient with indolent T-cell lymphoproliferative disease of the gastrointestinal tract","volume":"27","author":"Perry","year":"2019","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0194","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41375-019-0678-3","article-title":"Targetability of STAT3\u2013JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract","volume":"34","author":"Hu","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2021.12.191_bib0195","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1158\/1078-0432.CCR-14-1216","article-title":"Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma","volume":"21","author":"K\u00fc\u00e7\u00fck","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2021.12.191_bib0196","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MOH.0000000000000249","article-title":"The many layers of epigenetic dysfunction in B-cell lymphomas","volume":"23","author":"Jiang","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0197","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1182\/blood-2011-06-358382","article-title":"Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)","volume":"118","author":"Ralfkiaer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0198","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2021.12.191_bib0199","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2021.12.191_bib0200","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","article-title":"Advances in understanding of angioimmunoblastic T-cell lymphoma","volume":"34","author":"Chiba","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2021.12.191_bib0201","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/cancers13061414","article-title":"EBV and the pathogenesis of NK\/T cell lymphoma","volume":"13","author":"Montes-Mojarro","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.exphem.2021.12.191_bib0202","doi-asserted-by":"crossref","first-page":"17764","DOI":"10.18632\/oncotarget.3776","article-title":"Genetic alterations of JAK\/STAT cascade and histone modification in extranodal NK\/T-cell lymphoma nasal type","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2021.12.191_bib0203","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/gcc.22348","article-title":"Frequent BCOR aberrations in extranodal NK\/T-cell lymphoma, nasal type","volume":"55","author":"Dobashi","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.exphem.2021.12.191_bib0204","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2005-03-1306","article-title":"T-cell non-Hodgkin lymphoma","volume":"107","author":"Rizvi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0205","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/jcp.2010.084459","article-title":"Expression of follicular helper T cell markers in nodal peripheral T cell lymphomas: a tissue microarray analysis of 162 cases","volume":"64","author":"Zhan","year":"2011","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0206","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0207","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronn\u00e9","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2021.12.191_bib0208","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","article-title":"RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis","volume":"33","author":"Cortes","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2021.12.191_bib0209","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"33","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2021.12.191_bib0210","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0211","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","article-title":"Peripheral T-cell lymphoma, not otherwise specified","volume":"129","author":"Broccoli","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0212","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0213","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.hoc.2016.11.003","article-title":"Autologous and allogeneic hematopoietic cell transplantation in peripheral T\/NK-cell lymphomas: A histology-specific review","volume":"31","author":"Dhawale","year":"2017","journal-title":"Hematol\/Oncol Clin North Am"},{"key":"10.1016\/j.exphem.2021.12.191_bib0214","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.hoc.2008.07.010","article-title":"Peripheral T-cell non-Hodgkin's lymphoma","volume":"22","author":"Vose","year":"2008","journal-title":"Hematol\/Oncol Clin North Am"},{"key":"10.1016\/j.exphem.2021.12.191_bib0215","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2016.0117","article-title":"NCCN Guidelines Insights: Non-Hodgkin's lymphomas, Version 3.2016","volume":"14","author":"Horwitz","year":"2016","journal-title":"J Natl Compre Cancer Netw"},{"key":"10.1016\/j.exphem.2021.12.191_bib0216","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"Horwitz SM. How I treat the peripheral T-cell lymphomas","volume":"123","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0217","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0218","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0219","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and S\u00e9zary Syndrome: Effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0220","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0221","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/bloodadvances.2020001441","article-title":"Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma","volume":"4","author":"Iyer","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2021.12.191_bib0222","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2021.12.191_bib0223","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2021.12.191_bib0224","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-020-00380-5","article-title":"Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological features","volume":"10","author":"Argyropoulos","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2021.12.191_bib0225","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jid.2016.03.024","article-title":"Identification of gene mutations and fusion genes in patients with S\u00e9zary syndrome","volume":"136","author":"Prasad","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0226","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bjd.18098","article-title":"Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-\u03baB and nuclear factor of activated T cells pathways","volume":"182","author":"P\u00e9rez","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0227","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of S\u00e9zary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2021.12.191_bib0228","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0229","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jid.2020.07.026","article-title":"Phenotypical markers, molecular mutations, and immune microenvironment as targets for new treatments in patients with mycosis fungoides and\/or S\u00e9zary syndrome","volume":"141","author":"Quaglino","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0230","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: A multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0231","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3390\/cancers12082129","article-title":"Single-cell heterogeneity of cutaneous T-cell lymphomas revealed using RNA-Seq technologies","volume":"12","author":"Rassek","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.exphem.2021.12.191_bib0232","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO\u2013EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.12.191_bib0233","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/PAS.0000000000001449","article-title":"Clinical, histologic, and molecular characteristics of anaplastic lymphoma kinase-positive primary cutaneous anaplastic large cell lymphoma","volume":"44","author":"Melchers","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0234","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.jid.2020.02.019","article-title":"Recurrent oncogenic JAK and STAT alterations in cutaneous CD30-positive lymphoproliferative disorders","volume":"140","author":"Maurus","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0235","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41588-018-0251-4","article-title":"Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome","volume":"50","author":"Gayden","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2021.12.191_bib0236","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1182\/bloodadvances.2018028340","article-title":"Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma","volume":"3","author":"Polprasert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2021.12.191_bib0237","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/s41467-020-15572-7","article-title":"Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas","volume":"11","author":"Daniels","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2021.12.191_bib0238","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/gcc.22673","article-title":"Array-based CGH of primary cutaneous CD8+ aggressive EPIDERMO-tropic cytotoxic T-cell lymphoma","volume":"57","author":"Fanoni","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.exphem.2021.12.191_bib0239","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0002-9440(10)65144-9","article-title":"Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas: A distinct clinicopathological entity with an aggressive clinical behavior","volume":"155","author":"Berti","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0240","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/jdv.16969","article-title":"Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico-pathological and prognostic features","volume":"35","author":"Kempf","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.exphem.2021.12.191_bib0241","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.jdcr.2020.08.041","article-title":"Primary cutaneous peripheral T-cell lymphoma, not otherwise specified with mammalian target of rapamycin mutation: A novel finding for targeted treatment","volume":"6","author":"De la Sancha","year":"2021","journal-title":"JAAD Case Rep"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X21006226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X21006226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:13:01Z","timestamp":1777547581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X21006226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":241,"alternative-id":["S0301472X21006226"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2021.12.191","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in T-cell lymphoid neoplasms","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2021.12.191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}